- Conditions
- Macular Degeneration
- Interventions
- Abicipar Pegol, Ranibizumab, Sham Procedure
- Drug · Other
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 939 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 71
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Encino, California + 61 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1465–1488
of 8,148
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
- Interventions
- NX-5948
- Drug
- Lead sponsor
- Nurix Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Duarte, California • Los Angeles, California + 23 more
- Conditions
- Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm, Malignant Female Reproductive System Neoplasm, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Unresectable HER2-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
- Interventions
- Alpelisib, Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Echocardiography Test, Fluorouracil, Fulvestrant, Ipatasertib, Leucovorin, Magnetic Resonance Imaging, Multigated Acquisition Scan, Mutation Carrier Screening, Neratinib Maleate, Nilotinib Hydrochloride Monohydrate, Olaparib, Oxaliplatin, Paclitaxel, Palbociclib, Panitumumab, Positron Emission Tomography, Selumetinib Sulfate, Sotorasib
- Drug · Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 2,900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 479
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 355 more
- Conditions
- Severe Traumatic Brain Injury
- Interventions
- Observational
- Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 25 more
- Conditions
- Suicide
- Interventions
- Toward Hope, Recovery, Interpersonal Growth, Values, and Engagement (THRIVE), Center Care as Usual
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 552 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 3
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Nashville, Tennessee
- Conditions
- Melanoma, Advanced Melanoma, Metastatic Melanoma, Unresectable Melanoma
- Interventions
- CMP-001, Nivolumab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Duarte, California • Los Angeles, California + 21 more
- Conditions
- Postherpetic Neuralgia
- Interventions
- TV-45070, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 77
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more
- Conditions
- Primary Disease or Condition Being Studied: Angelman Syndrome (AS)
- Interventions
- Gaboxadol, Placebo
- Drug
- Lead sponsor
- Ovid Therapeutics Inc.
- Industry
- Eligibility
- 2 Years to 12 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • San Diego, California • Chicago, Illinois + 6 more
- Conditions
- Lymphoma
- Interventions
- Parsaclisib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 18 more
- Conditions
- HIV Infections
- Interventions
- TNX-355
- Drug
- Lead sponsor
- Tanox
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 8 more
- Conditions
- Age-related Macular Degeneration
- Interventions
- AGN-150998, ranibizumab, Sham Injection
- Drug · Other
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 271 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Burns
- Interventions
- Enteral Glutamine, Placebo
- Dietary Supplement
- Lead sponsor
- Daren K. Heyland
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2021
- U.S. locations
- 27
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 24 more
- Conditions
- Chronic Kidney Disease, Cardiovascular Disease, Death
- Interventions
- High Dose Multivitamin, Low Dose Multivitamin
- Drug · Device
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 35 Years to 75 Years
- Enrollment
- 4,110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2011
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 22 more
- Conditions
- Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Interventions
- docetaxel
- Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 53 more
- Conditions
- Hepatobiliary Cancers
- Interventions
- Durvalumab-based combination therapies in observational study setting, Non Durvalumab-based therapies in observational study setting, Durvalumab-based combination therapies in observational study settings
- Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 4,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 21 more
- Conditions
- Diabetes, Type 1, Diabetes, Type 2
- Interventions
- Technosphere® Insulin Inhalation Powder, Usual Care
- Drug
- Lead sponsor
- Mannkind Corporation
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 2,053 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2008
- U.S. locations
- 82
- States / cities
- Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 64 more
- Conditions
- Kidney Transplantation
- Interventions
- FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids, FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids, MMF 2 g + full-dose Neoral (FDN) + corticosteroids
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 696 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 42
- States / cities
- Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 36 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- FF/GW642444 Inhalation Powder, GW642444 Inhalation Powder
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 1,626 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 94
- States / cities
- Birmingham, Alabama • Jasper, Alabama • Peoria, Arizona + 85 more
- Conditions
- Multiple Sclerosis
- Interventions
- Protective step training
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 20 Years to 80 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Major Depressive Disorder
- Interventions
- Antidepressant + placebo, Antidepressant + cariprazine (0.1-0.3 mg/day), Antidepressant + cariprazine (1-2 mg/d)
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 231 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 41
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Arcadia, California + 35 more
- Conditions
- Aneuploidy, Down Syndrome, Noninvasive Prenatal Screening
- Interventions
- SEQureDx Trisomy Test
- Device
- Lead sponsor
- Sequenom, Inc.
- Industry
- Eligibility
- 18 Years to 34 Years · Female only
- Enrollment
- 3,333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 27
- States / cities
- Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 22 more
- Conditions
- Fibromyalgia
- Interventions
- Duloxetine, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 13 Years to 17 Years
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Loma Linda, California • National City, California + 23 more
- Conditions
- Glioma
- Interventions
- 5-ala
- Drug
- Lead sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Alzheimer's Disease, Dementia
- Interventions
- EVP-6124
- Drug
- Lead sponsor
- FORUM Pharmaceuticals Inc
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 348 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 56
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 53 more